THCB UPDATE Get email updates of new posts and industry news.

May 09, 2008

Wal-Mart drops drug prices, shakes up market -- again

Wal-Mart continued its first-mover tactics in health by dropping the price of prescriptions again. This time, the target is maintenance meds, which Wal-Mart will price at $10 for a 90-days supply.

This move puts Wal-Mart squarely in the pharmacy benefits management (PBM) segment vis-à-vis ExpressScripts, Medco, and the big PBM players. The three-month mail order med business is the lucrative turf of PBMs. Wal-Mart's first move into this space was in 2006 when the company priced many 30-day prescriptions at $4, shaking up the industry. I wrote about that market disruption here in January 2008.

Wal-Mart will also offer over 1,000 over-the-counter (OTC) meds for $4 and under. These will all be Wal-Mart's private labels for popular OTC brands.

As the company with the red bulls-eye did the last time Wal-Mart dropped the price of meds, Target responded as a fast follower by saying they, too, will match the Wal-Mart prices for a 90-day supply of drugs. Target's program will expand the assortment of $4 Rx drugs and the 90-day supply of these medications for $10 and private-label OTC medications for $4 or less.

While price transparency is what retail pharmacy should be all about, Consumer Reports found that prices across and even within pharmacy chains can significantly vary -- by $100 or more from the same drug, from store to store and within the chain.

Consumer Reports surveyed pharmacies' prices for three brand-name meds and one generic drug. The range of retail prices for each drug were:

  • Pfizer’s urinary incontinence drug Detrol = $365 to $551
  • BMS's and Sanofi-Aventis' blood clot drug Plavix = $382 to $541
  • King Pharmaceuticals’ hypothyroid drug Levoxyl = $29 to $85
  • Generic Fosamax for osteoporosis (alendronate) = $124 to $306.

Consumer Reports also found that independent pharmacies can be price-competitive, given these price ranges, and can offer a higher level of service -- especially access to pharmacists for personal consults.

In another prescription drug update, a study published in the American Journal of Public Health found that one in four Americans share or "borrow" prescription drugs from each other. Most common shared drugs include those for categories in allergy, pain (like Darvocet and Oxycontin), and antibiotics.

Women are twice as likely to share prescription drugs as men.

Jane's Hot Points: Almost one-third of Wal-Mart's nonprescription drugs now sell for $4 or less, luring people also shopping for groceries and clothes. The price of gas is a powerful incentive for consumers to look for one-stop shopping, and Wal-Mart can deliver on this.

That consumers respond to price incentives for prescription drug shopping is in general healthy; it's a rational economic response from the pages of Adam Smith and market theory. That people "share" drugs like OxyContin and antibiotics, however, is a rational economic response; but not sound public health. Here's an example of where market forces can drive bad health behavior.

May 9, 2008 in Jane Sarasohn-Kahn, The Industry | Permalink

Comments

It is a big deal and should save people money. Getting 90-day supply and including OTCs certainly should have surprised a few people and made some consumers save money.

Will it move marketshare is the key question? People aren't as sticky to their pharmacy as they once were.

At what volume is it profitable for WalMart to do this or is it a loss leader for traffic?

And, I think an interesting question is whether you could ever see a pharmacy plan that only covers the brand drugs. A few years ago, I thought you would see a generic only PBM offering, but with this, you might be able to go the other way.

Of course, I still continue to emphasize the fact that getting the claims aggregated within a PBM is important for DUR (drug utilization review) (i.e., drug-drug interactions) so paying cash at WalMart and others (if you have insurance) is not the right strategy.

www.georgevanantwerp.com

Posted by: George Van Antwerp | May 9, 2008 9:26:45 AM

Interesting. If I understand this correctly, walmart offers very low pricing for generics and OTC drugs?

I do not have the numbers to back my claim up, but I recently had a drug rep in my office who detailed a drug that will soon loose patent protection. As I reminded her about upcoming generics, she said: "There are not that many generic drug makers any more." (don't know whether she is right, anyone here knows?)I also know that some pharmaceutical companies pay generic manufacturers NOT to produce the generic.

Could it be that walmart's strategy to be the cheap retail giant corrects the anticompetitive practices of drug companies?

Posted by: bobo | May 9, 2008 12:21:13 PM

Wal-Mart understands the increasingly "cosumer-driven" market. Check out www.medsane.com for other cost-effective medication options.

Posted by: rational prescriber | May 9, 2008 5:35:34 PM

George, you know that brand-only design is coming. At least 2 insurers/pbms have had it in the works for a couple of years, prodded by employers as I understand it.

Also agree with you on the quality of care issues that come from fragmented data. One possible, partial solution; id card that doubles (or triples) as information token and payment form, so any retail transactions are passed to consumer's choice of data aggregator(s). Again, the technology is already developed (and I'm not referring to the debit/credit card systems used by HSA processors. Conventional processing rails are ok only for very limited data processing/sharing. They can mostly manage the financial transaction data, but are a poor option for any clinical data that completes the picture).

And again, awareness & adoption pressure from employers would help.

Posted by: weekend health kibitzer | May 10, 2008 3:17:16 PM

Of all the healthcare segments, pharmacy is the most convoluted. PBMs started as record keeping and eligibiility services and continued to do more and more to increase income streams. Predatory pricing, retention of point spreads, rebates and games with wholesale pricing in mail order has made them incredcibly wealthy. They do no research, manufacture no product, warehouse no supplies and distribute no product, yet make more than most of the other players in the industry. A large fine is nothing to them and they just continue their practices. With pharmacy being an average of 20% to 22% of claims paid, it is time something was done to stop the obscene profits and payscale of the top officers.

Posted by: Bill Bennett | May 12, 2008 5:43:15 AM

Post a comment